Physician profile
Cuong Pham
NPI 1386658433
$1,585.37
in general payments reported to CMS, 2019-2025
13 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $275 · 2023: $531 · 2024: $335 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049 · Entertainment: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.02 |
| Entertainment | $103.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $283.46 | 2021-2024 | |
| Alcon Vision LLC | $264.04 | 2021-2024 | Total30 |
| Bausch & Lomb Americas INC. | $140.06 | 2022-2023 | Infuse |
| Johnson & Johnson Surgical Vision, INC. | $136.81 | 2025 | Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $119.27 | 2023 | Cequa |
| Biotissue Holdings INC. | $108.20 | 2024 | |
| Optos, INC. | $103.46 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $97.03 | 2024 | Misight Contact Lens |
| Oyster Point Pharma, INC. | $80.00 | 2023 | Tyrvaya |
| Dompe US, INC. | $78.46 | 2025 | Oxervate |
| Ocular Therapeutix, INC. | $70.69 | 2025 | Dextenza |
| Topcon Healthcare, INC. | $64.68 | 2023 | |
| Lkc Technologies, INC. | $39.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cuong Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.